Nevro has gained FDA approval for HFX AdaptivAI, an advanced AI-driven platform designed to personalize spinal cord stimulation (SCS) therapy. The company initiated a limited release, with plans for a full U.S. market launch in Q4 2024. This innovation offers real-time therapy adjustments based on patient feedback, using millions of data points.
HFX AdaptivAI allows patients to control their pain management while offering remote monitoring for physicians. Despite this milestone, Nevro faces market competition challenges. CEO Kevin Thornal emphasized that this technology reaffirms Nevro’s commitment to providing personalized, responsive pain relief solutions for chronic pain patients.
The approval comes as Nevro navigates a competitive SCS market and explores strategic alternatives for growth.
Click here to read the original news story.